<p>AIC and BIC of survival curve in two groups.</p>

XueYin Xu published a dataset on figshare in May 2026 containing results from a partitioned survival model for advanced hepatocellular carcinoma. The 5.5 KB Excel file compares the cost-effectiveness of a dual-agent therapy versus sorafenib from the perspective of the Chinese healthcare system. The analysis uses a 10-year time horizon and a willingness-to-pay threshold of 299,400 CNY.

Use Cases

• Compare incremental cost-effectiveness ratios (ICERs) based on quality-adjusted life years (QALYs) mentioned in the description
• Conduct one-way sensitivity analysis on parameters like utility values and drug costs referenced in the results
• Perform probabilistic sensitivity analysis using the willingness-to-pay threshold of 299,400 CNY described
• Model partitioned survival outcomes for advanced hepatocellular carcinoma treatments as outlined in the methods

Strengths

• Dataset is small (5.5 KB), facilitating quick download and inspection
• Analysis is based on a Phase III clinical trial, suggesting a foundation in empirical data
• Model parameters are explicitly defined, including a 10-year horizon and a 4.5% discount rate

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect geographic bias inherent to the Chinese healthcare system perspective

Provenance

Source

figshare

Collection Method

Constructed from the results of a Phase III clinical trial using a three-state partitioned survival model.

Time Range

Model uses a 10-year time horizon.

Freshness

Last updated 2026-05-14 17:39:53; freshness should be verified

Geography

Analysis is from the perspective of the Chinese healthcare system.